Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 14 of 14 entries
View as:

Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product

Phase: N/A Priority: Normal
NCT ID: NCT02698579 Org: User:
Start: 01/22/16 End: 08/31/38 Due: 08/31/39

A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

Phase: N/A Priority: Normal
NCT ID: NCT01896102 Org: User:
Start: 08/21/13 End: 03/26/21 Due: 03/26/22

A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT02151526 Org: User:
Start: 06/07/13 End: 02/26/19 Due: 02/26/20

Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

Phase: N/A Priority: Normal
NCT ID: NCT02204904 Org: User:
Start: 04/30/15 End: 12/06/19 Due: 12/06/20

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia

Phase: N/A Priority: Normal
NCT ID: NCT03207009 Org: User:
Start: 06/08/17 End: 11/15/22 Due: 11/15/23

A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

Phase: N/A Priority: Normal
NCT ID: NCT03852498 Org: User:
Start: 01/24/19 End: 07/24/23 Due: 07/24/24

A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel

Phase: N/A Priority: Normal
NCT ID: NCT06224413 Org: User:
Start: 03/27/24 End: 12/30/47 Due: 12/30/48

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

Phase: N/A Priority: Normal
NCT ID: NCT02906202 Org: User:
Start: 08/08/16 End: 03/31/22 Due: 03/31/23

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02633943 Org: User:
Start: 01/31/14 End: 11/30/35 Due: 11/30/36

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

Phase: N/A Priority: Normal
NCT ID: NCT01745120 Org: User:
Start: 08/31/13 End: 02/21/18 Due: 02/21/19

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT04293185 Org: User:
Start: 02/14/20 End: 11/30/27 Due: 11/30/28

A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT02140554 Org: User:
Start: 02/02/15 End: 01/30/24 Due: 01/30/25

A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel

Phase: N/A Priority: Normal
NCT ID: NCT06271512 Org: User:
Start: 01/23/24 End: 12/31/43 Due: 12/31/44

Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy

Phase: N/A Priority: Normal
NCT ID: NCT04628585 Org: User:
Start: 10/21/20 End: 01/31/38 Due: 01/31/39